Media & Events
Shardul Amarchand Mangaldas & Co. advises Biocon Limited on its ₹4,150 crore Qualified Institutions Placement
January 15, 2026
Shardul Amarchand Mangaldas & Co. (“SAM”) acted as legal counsel to Biocon Limited on its ₹4,150 crore (approximately USD 460 million) Qualified Institutions Placement (“QIP”) of equity shares.
The QIP was undertaken in pursuance of Biocon’s strategy to fully integrate its subsidiary, Biocon Biologics Limited by combining businesses, and witnessed participation from leading institutional investors. The QIP proceeds are proposed to be used for payment of cash consideration to Mylan Inc. for acquisition of shares of Biocon Biologics Limited and repayment of related debt availed by the Company, repayment of debt availed in respect of the acquisition of compulsorily convertible debentures of Biocon Biologics Limited held by affiliates of Edelweiss and general corporate purposes.
The SAM transaction team was led by Prashant Gupta, National Practice Head – Capital Markets, and Ruth Chenchiah, Partner, and comprised Debolina Mitra, Senior Associate; Kunika Agarwal, Associate; and Dipti Tharwani, Associate.